How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
Détails
ID Serval
serval:BIB_B76219102FFE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
Périodique
BJU international
Collaborateur⸱rice⸱s
European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP)
ISSN
1464-410X (Electronic)
ISSN-L
1464-4096
Statut éditorial
Publié
Date de publication
11/2018
Peer-reviewed
Oui
Volume
122
Numéro
5
Pages
823-830
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
To develop a novel tool to increase the number of patients with prostate cancer eligible for active surveillance (AS) without increasing the risk of unfavourable pathological features (i.e., misclassification) at radical prostatectomy (RP).
Overall, 16 049 patients with low- or intermediate-risk prostate cancer treated with RP were identified. Misclassification was defined as non-organ confined or grade group ≥3 disease at RP. The coefficients of a logistic regression model predicting misclassification were used to develop a risk score. We then performed a systematic analysis of different thresholds to discriminate between patients with or without unfavourable disease and we compared it to available AS criteria.
Overall, 5289 (33.0%) patients had unfavourable disease. At multivariable analyses, PSA level, clinical stage, biopsy grade group, the number of positive cores, and PSA density were associated with the risk of unfavourable disease (all P < 0.001). The Prostate Cancer Research International: Active Surveillance (PRIAS) criteria were associated with a lower risk of misclassification (13%) compared to other criteria. Overall, 3303 (20.6%) patients were eligible according to the PRIAS protocol. The adoption of an 18% threshold according to the risk score increased the proportion of eligible patients from 20.6% to 29.4% without increasing the risk of misclassification as compared to the PRIAS criteria.
The use of a novel risk score for AS selection would result in an absolute increase of 10% in the number of patients eligible for this approach without increasing the risk of misclassification.
Overall, 16 049 patients with low- or intermediate-risk prostate cancer treated with RP were identified. Misclassification was defined as non-organ confined or grade group ≥3 disease at RP. The coefficients of a logistic regression model predicting misclassification were used to develop a risk score. We then performed a systematic analysis of different thresholds to discriminate between patients with or without unfavourable disease and we compared it to available AS criteria.
Overall, 5289 (33.0%) patients had unfavourable disease. At multivariable analyses, PSA level, clinical stage, biopsy grade group, the number of positive cores, and PSA density were associated with the risk of unfavourable disease (all P < 0.001). The Prostate Cancer Research International: Active Surveillance (PRIAS) criteria were associated with a lower risk of misclassification (13%) compared to other criteria. Overall, 3303 (20.6%) patients were eligible according to the PRIAS protocol. The adoption of an 18% threshold according to the risk score increased the proportion of eligible patients from 20.6% to 29.4% without increasing the risk of misclassification as compared to the PRIAS criteria.
The use of a novel risk score for AS selection would result in an absolute increase of 10% in the number of patients eligible for this approach without increasing the risk of misclassification.
Mots-clé
Aged, Biopsy, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prostate/pathology, Prostate/surgery, Prostatectomy/statistics & numerical data, Prostatic Neoplasms/diagnosis, Prostatic Neoplasms/epidemiology, Prostatic Neoplasms/pathology, Prostatic Neoplasms/surgery, Retrospective Studies, Risk Assessment, #PCSM, #ProstateCancer, misclassification, pathological outcomes, radical prostatectomy
Pubmed
Web of science
Création de la notice
24/05/2018 17:41
Dernière modification de la notice
20/08/2019 15:25